A double-blind, placebo controlled single and multiple ascending dose Phase I clinical trial will evaluate the safety, tolerability, and pharmacokinetics of ISM001-055
Latest Information Update: 04 Mar 2022
At a glance
- Drugs Rentosertib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
Most Recent Events
- 04 Mar 2022 New trial record
- 24 Feb 2022 According to an InSilico Medicine media release, company has dosed multiple healthy volunteers in this trial.